EHA 2026 | Isatuximab on-body injector may improve myeloma care delivery and patient experience

Isatuximab is becoming the standard of care in many settings in multiple myeloma, from frontline to relapsed refractory population. It is a new generation, since the 38th monoclonal antibody, and we know that in this moment we are obliged to perform intravenously the administrations of the drug. OBI is a revolution. It has been tested inside a double clinical trial. Heraclea in combination with pomalidomide and dexamethasone and Izalco with carfilzomib and dexamethasone. Both of the trials were in a relapsed and refractory setting. They were studies of non-inferiority. And coming from the data in terms of effectiveness, it is absolutely the same, intravenous versus subcutaneous, but in terms of tolerability and the patient’s reported outcomes, the OBI is a great addition, a game changer of this atuximab-based treatment. This is like a small button that we put on the abdomen of the patient. Intradermally, we injected the drug, and this is safe, this is simple, so simple that inside clinical trials, there was a small cohort of patients that administered in a domestic setting. We had the possibility to take the anti-CD38 treatment at home, and I think this is a revolution in the revolution for applying this revolution to also other combinations because we know that recently Isatuximab has been approved also in elderly frontline setting in transplant ineligible patients, BRD is an exciting solution, the idea to perform subcutaneously with a so safe device is something that has the possibility to treat many patients with that. And also in terms of the possibility that in frontline transplant eligible setting, thanks to GMMG HD7, Isatuximab will be approved. I think that we can switch all the patients to subcutaneous administration. The patient’s reported outcomes are one important point, but also the feedback they’re having from the hospital staff is really important, and particularly the nurses and the physicians that had to manage this patient are particularly happy to not inject directly on the skin, but injecting into the tool is something that helps also some patients that are afraid of the injection itself and in general don’t want to be cut so many times according to the administration of the drug. I think that in this moment we have so many novelties about myeloma that this is a way to think also about the quality of daily life of our patients and not only to improve the effectiveness of the triplets, quadruplets and all the drugs that we have available. So in the next future, I hope that more solutions like this will be available to improve the life of our patients.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.